With $69M D round, Adagene looks to Phase II for solid, blood cancers

Adagene plans to use a $69 million series D round take its solid tumor and non-Hodgkin lymphoma candidate into the first Phase II trial for an antibody developed with the company's computational design platform.

The series D round includes $50 million from lead investor General

Read the full 447 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers